Brandes Investment Partners’s Oragenics OGEN Stock Holding History

Brandes Investment Partners’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1	Closed	-$6K	–	196
2017 Q1	$6K	Buy	+1	New	+$10.8K	﹤0.01%	201

Other funds holding OGEN

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Brandes Investment Partners's OGEN Position: Q2 2017 in Review

Brandes Investment Partners sold out of Oragenics (OGEN) in Q2 2017, closing a stake of 1 share — an estimated $6K sold.

Brandes Investment Partners first reported a position in OGEN in Q1 2017 and held it in 1 quarter. The position peaked at $6K in Q1 2017. 12 funds tracked by Wall St. Rank hold OGEN as of Q2 2017.

Brandes Investment Partners reported no remaining Oragenics position as of Q2 2017 after selling out during the quarter.
Brandes Investment Partners sold 1 Oragenics share in Q2 2017, an estimated $6K.
Brandes Investment Partners first reported a position in Oragenics in Q1 2017 and held it in 1 quarter.
Brandes Investment Partners's Oragenics position peaked at $6K in Q1 2017.
12 funds tracked by Wall St. Rank held Oragenics as of Q2 2017.

Based on Brandes Investment Partners's 13F filing for Q2 2017, filed 9 Aug 2017.